The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology
Open accessAbstract
Second generation antipsychotics (SGAs), such as clozapine, olanzapine, risperidone and quetiapine, are among the most effective therapies to stabilize symptoms schizophrenia (SZ) spectrum disorders. In fact, clozapine, olanzapine and risperidone have improved the quality of life of billions SZ patients worldwide. Based on the broad spectrum of efficacy and low risk of extrapyramidal symptoms displayed by SGAs, some regulatory agencies approved the use of SGAs in non-schizophrenic adults, children and adolescents suffering from a range of neuropsychiatric disorders. However, increasing number of reports have shown that SGAs are strongly associated with accelerated weight gain, insulin resistance, diabetes, dyslipidemia, and increased cardiovascular risk. These metabolic alterations can develop in as short as six months after the initiation of pharmacotherapy, which is now a controversial fact in public disclosure. Although the percentage of schizophrenic patients, the main target group of SGAs, is estimated in only 1% of the population, during the past ten years there was an exponential increase in the number of SGAs users, including millions of non-SZ patients. The scientific bases of SGAs metabolic side effects are not yet elucidated, but the evidence shows that the activation of transcriptional factor SRBP1c, the D1/D2 dopamine, GABA2 and 5HT neurotransmitions are implicated in the SGAs cardiovascular toxicity. Polypharmacological interventions are either non- or modestly effective in maintaining low cardiovascular risk in SGAs users. In this review we critically discuss the clinical and molecular evidence on metabolic alterations induced by SGAs, the evidence on the efficacy of classical antidiabetic drugs and the emerging concept of antidiabetic polyphenols as potential coadjutants in SGA-induced metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 2×
“The group of SGAs includes drugs with different chemical strucures, mode of action and risk profile for metabolic side effects, eing olanzapine the most toxic drug of this group followed by lozapine, risperidone, quetiapine and aripiprazole [130,31].”
BackgroundWu, R.-R., Zhao, J.-P., Jin, H., Shao, P., Fang, M.-S., Guo, X.-F., He, Y.-Q., Liu, Y.-J., Chen, J.-D., & Li, L.-H. (2008) · JAMA · doi:10.1001/jama.2007.56-b · Cited by 366 · cited 10×
“Treatment with metformin in patients treated with OLZ decreased body mass index and weight gain, no changes in insulin levels and insulin resistance Positive [93] Metformin 850–1750 mg/day Double-blind placebo-controlled trial 40 3.5 Body weight gain, HOMA-IR Metformin decreased HOMA-IR and glucose levels.”
BackgroundInfluentialChen, S., Zhao, X., Ran, L., Wan, J., Wang, X., Qin, Y., Shu, F., Gao, Y., Yuan, L., Zhang, Q., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.11.015 · Cited by 319 · cited 11×
“Elevated adiponectin Positive [26] Green tea (Camellia sinensis) Randomized controlled trial 35 8 weeks Parameters, of metabolic syndrome No change in metabolic syndrome features, a decrease in plasma amyloid alpha Negative [14] Whole blueberries 22.5 g, twice a day Double-blinded, randomized, and…”
BackgroundInfluentialGreen tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome
Basu, A., Du, M., Sanchez, K., Leyva, M. J., Betts, N. M., Blevins, S., Wu, M., Aston, C. E., & Lyons, T. J. (2011) · Nutrition · doi:10.1016/j.nut.2010.01.015 · Cited by 194
Graham, K. A., Gu, H., Lieberman, J. A., Harp, J. B., & Perkins, D. O. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.9.1744 · Cited by 92
Roopchand, D. E., Krueger, C. G., Moskal, K., Fridlender, B., Lila, M. A., & Raskin, I. (2013) · Food Chemistry · doi:10.1016/j.foodchem.2013.06.050 · Cited by 73 · cited 1×
“utritional studies suggest that anthocyanins from diverse dietary ources are potent anti-diabetic, anti-obesity and cardioprotective olecules [57,100,99,27,36].”
Background
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications
Penninx, B. W. J. H., & Lange, S. M. M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/bpenninx · Cited by 566
Rosmarinus officinalis L. (rosemary) as therapeutic and prophylactic agent
de Oliveira, J. R., Camargo, S. E. A., & de Oliveira, L. D. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0499-8 · Cited by 367
Metadata
- Authors
- Rojo, L. E., Gaspar, P. A., Silva, H., Risco, L., Arena, P., Cubillos-Robles, K., & Jara, B.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 101
- Pages
- 74-85
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W1011353509
- Cited by
- 218
- References
- 6
- FWCI
- 14.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. https://app.cochat.ai/papers/10.1016/j.phrs.2015.07.022
- The paper
- Rojo, L. E., Gaspar, P. A., Silva, H., Risco, L., Arena, P., Cubillos-Robles, K., & Jara, B. (2015). Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacological Research. https://doi.org/10.1016/j.phrs.2015.07.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.